Sugi Predict

Sugi Predict / Compounds / SCHEMBL27147155

SCHEMBL27147155

SCHEMBL27147155

C=C(NC(=O)c1csc(N2CCN(C(=O)COCCOC)CC2)n1)C(=O)NC(=C)C(=O)OC

nearest known ligand 0.35

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ HRH3 Q9Y5N1 2/20 0.35
▸ LMNA P02545 2/20 0.35
▸ MAPT P10636 2/20 0.35
▸ MAPK1 P28482 2/20 0.35
▸ SMN1; SMN2 Q16637 1/20 0.35
▸ MEN1 O00255 4/20 0.35
▸ KMT2A Q03164 4/20 0.35
▸ L3MBTL1 Q9Y468 2/20 0.33
▸ RAB9A P51151 2/20 0.33
▸ OGA O60502 1/20 0.33
▸ NPC1 O15118 1/20 0.33
▸ EPHX2 P34913 1/20 0.33
▸ ALDH1A1 P00352 2/20 0.33
▸ NAMPT P43490 1/20 0.33
▸ POLB P06746 1/20 0.33
▸ HPGD P15428 1/20 0.33
▸ BLM P54132 1/20 0.33
▸ ESR2 Q92731 1/20 0.33
▸ TDP1 Q9NUW8 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31364477 0.89 HRH3 (0.38) HRH3LMNAMAPTMAPK1SMN1; SMN2
SCHEMBL27142108 0.84 ACKR3 (0.37) HRH3MEN1KMT2AOGAALDH1A1
SCHEMBL27151795 0.83 HRH3 (0.34) HRH3LMNAMEN1KMT2AL3MBTL1
SCHEMBL27150696 0.82 ACKR3 (0.41) HRH3LMNAMAPTMAPK1SMN1; SMN2
SCHEMBL27145076 0.80 ACKR3 (0.38) HRH3LMNAMEN1KMT2AL3MBTL1
SCHEMBL27145196 0.80 L3MBTL1 (0.48) LMNAKMT2AL3MBTL1
SCHEMBL27105575 0.78 ACKR3 (0.39) HRH3MEN1KMT2AOGAALDH1A1
SCHEMBL27105606 0.78 KDM4E (0.51) LMNAMAPTSMN1; SMN2ALDH1A1POLB
SCHEMBL30807308 0.78 PIN1 (0.43) HRH3LMNAMAPTMAPK1SMN1; SMN2
SCHEMBL30807271 0.78 LMNA (0.40) HRH3LMNAMAPTMAPK1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260062407-A1 PEROXIREDOXIN 3 INHIBITORS AND METHODS OF USE FOR TREATING CANCER UNIV WAKE FOREST HEALTH SCIENCES (US) 2026-03-05 — — US disclosed
US-20250381278-A1 PEROXIREDOXIN 3 INHIBITORS AND METHODS OF USE FOR TREATING CANCER UNIV WAKE FOREST HEALTH SCIENCES (US) 2025-12-18 — — US disclosed
EP-4577211-A2 PEROXIREDOXIN 3 INHIBITORS AND METHODS OF USE FOR TREATING CANCER Wake Forest University Health Sciences (US) 2025-07-02 — — EP disclosed
US-20250011316-A1 PEROXIREDOXIN 3 INHIBITORS AND METHODS OF USE FOR TREATING CANCER WAKE FOREST UNIVERSITY HEALTH SCIENCES 2025-01-09 — — US disclosed
WO-2024044744-A2 PEROXIREDOXIN 3 INHIBITORS AND METHODS OF USE FOR TREATING CANCER WAKE FOREST UNIVERSITY HEALTH SCIENCES (US) 2024-02-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260062407-A1 PEROXIREDOXIN 3 INHIBITORS AND METHODS OF USE FOR TREATING CANCER PRDX1, PRDX3, PRDX2 HRH3 2753/4885LMNA 2939/4885MAPT 4676/4885
US-20250011316-A1 PEROXIREDOXIN 3 INHIBITORS AND METHODS OF USE FOR TREATING CANCER PRDX1, PRDX2, PRDX6 HRH3 3251/4885LMNA 2798/4885MAPT 4743/4885
US-20250381278-A1 PEROXIREDOXIN 3 INHIBITORS AND METHODS OF USE FOR TREATING CANCER PRDX1, PRDX2, PRDX6 HRH3 3377/4885LMNA 2786/4885MAPT 4754/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.